The GGN and CAG repeat polymorphisms in the exon-1 of the androgen receptor gene are, respectively, associated with insulin resistance in men and with dyslipidemia in women

Journal of Steroid Biochemistry and Molecular Biology

Volumn 113, Issue 3-5, 2009, Pages 202-208

  Rodríguez González, Germán ^a,b   Ramírez Moreno, Raquel ^a,b   Pérez, Patricia ^a,b   Bilbao, Cristina ^a,b   López Ríos, Laura ^a,b   Díaz Chico, Juan C ^a,b   Lara, Pedro C ^a,b   Serra Majem, Lluis ^a,b   Chirino, Ricardo ^a,b   Díaz Chico, B Nicolás ^a,b  

^a Madrid Spain   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

Androgen receptor; CAG repeat polymorphism; GGN repeat polymorphism; Insulin; Insulin resistance; Low density lipoprotein cholesterol

Indexed keywords

ANDROGEN RECEPTOR; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DNA POLYMORPHISM; DYSLIPIDEMIA; EXON; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PARAMETER; PATHOGENESIS; TRINUCLEOTIDE REPEAT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DYSLIPIDEMIAS; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN; SPAIN; TRINUCLEOTIDE REPEATS; YOUNG ADULT;

EID: 61349092269     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.12.009     Document Type: Article

References (62)

1. Rodriguez G., Bilbao C., Ramirez R., Falcon O., Leon L., Chirino R., Falcon Jr. O., Diaz B.P., Rivero J.F., Perucho M., Diaz-Chico B.N., and Diaz-Chico J.C. Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. Int. J. Cancer 118 6 (2006) 1420-1425
2. Jenster G., van der Korput H.A., Trapman J., and Brinkmann A.O. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem. 270 13 (1995) 7341-7346
3. Ding D., Xu L., Menon M., Reddy G.P., and Barrack E.R. Effect of a short CAG (glutamine) repeat on human androgen receptor function. Prostate 58 1 (2004) 23-32
4. Wang Q., Udayakumar T.S., Vasaitis T.S., Brodie A.M., and Fondell J.D. Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells. J. Biol. Chem. 279 17 (2004) 17319-17328
5. Edwards S.M., Badzioch M.D., Minter R., Hamoudi R., Collins N., Ardern-Jones A., Dowe A., Osborne S., Kelly J., Shearer R., Easton D.F., Saunders G.F., Dearnaley D.P., and Eeles R.A. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int. J. Cancer 84 5 (1999) 458-465
6. Chamberlain N.L., Driver E.D., and Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucl. Acids Res. 22 15 (1994) 3181-3186
7. Schoenberg M.P., Hakimi J.M., Wang S., Bova G.S., Epstein J.I., Fischbeck K.H., Isaacs W.B., Walsh P.C., and Barrack E.R. Microsatellite mutation (CAG24 → 18) in the androgen receptor gene in human prostate cancer. Biochem. Biophys. Res. Commun. 198 1 (1994) 74-80
8. Tut T.G., Ghadessy F.J., Trifiro M.A., Pinsky L., and Yong E.L. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J. Clin. Endocrinol. Metab. 82 11 (1997) 3777-3782
9. Beilin J., Ball E.M., Favaloro J.M., and Zajac J.D. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J. Mol. Endocrinol. 25 1 (2000) 85-96
10. Ding D., Xu L., Menon M., Reddy G.P., and Barrack E.R. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate 62 2 (2005) 133-139
11. von Eckardstein A., Castro G., Wybranska I., Theret N., Duchateau P., Duverger N., Fruchart J.C., Ailhaud G., and Assmann G. Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-I (ApoA-I) variants with murine adipocytes and macrophages. Evidence for reduced cholesterol efflux promotion by apoA-I (Pro165 → Arg). J. Biol. Chem. 268 4 (1993) 2616-2622
12. Dowsing A.T., Yong E.L., Clark M., McLachlan R.I., de Kretser D.M., and Trounson A.O. Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene. Lancet 354 9179 (1999) 640-643
13. Mifsud A., Sim C.K., Boettger-Tong H., Moreira S., Lamb D.J., Lipshultz L.I., and Yong E.L. Trinucleotide (CAG) repeat polymorphisms in the androgen receptor gene: molecular markers of risk for male infertility. Fertil. Steril. 75 2 (2001) 275-281
14. Kukuvitis A., Georgiou I., Bouba I., Tsirka A., Giannouli C.H., Yapijakis C., Tarlatzis B., Bontis J., Lolis D., Papadimas N., and Sofikitis J. Association of oestrogen receptor alpha polymorphisms and androgen receptor CAG trinucleotide repeats with male infertility: a study in 109 Greek infertile men. Int. J. Androl. 25 3 (2002) 149-152
15. Hakimi J.M., Schoenberg M.P., Rondinelli R.H., Piantadosi S., and Barrack E.R. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin. Cancer Res. 3 9 (1997) 1599-1608
16. Navarro D., Luzardo O.P., Fernandez L., Chesa N., and Diaz-Chico B.N. Transition to androgen-independence in prostate cancer. J. Steroid Biochem. Mol. Biol. 81 3 (2002) 191-201
17. Yu H., Bharaj B., Vassilikos E.J., Giai M., and Diamandis E.P. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res. Treat. 59 2 (2000) 153-161
18. Nicolas Diaz-Chico B., German Rodriguez F., Gonzalez A., Ramirez R., Bilbao C., Cabrera de Leon A., Aguirre Jaime A., Chirino R., Navarro D., and Diaz-Chico J.C. Androgens and androgen receptors in breast cancer. J. Steroid Biochem. Mol. Biol. (2007)
19. Zitzmann M., Brune M., Kornmann B., Gromoll J., von Eckardstein S., von Eckardstein A., and Nieschlag E. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J. Clin. Endocrinol. Metab. 86 10 (2001) 4867-4873
20. Zitzmann M., and Nieschlag E. Androgens and vascular function. J. Endocrinol. Invest. 26 8 (2003) 767-769
21. Alevizaki M., Cimponeriu A.T., Garofallaki M., Sarika H.L., Alevizaki C.C., Papamichael C., Philippou G., Anastasiou E.A., Lekakis J.P., and Mavrikakis M. The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men. Clin. Endocrinol. (Oxf.) 59 6 (2003) 749-755
22. Mohlig M., Jurgens A., Spranger J., Hoffmann K., Weickert M.O., Schlosser H.W., Schill T., Brabant G., Schuring A., Pfeiffer A.F., Gromoll J., and Schofl C. The androgen receptor CAG repeat modifies the impact of testosterone on insulin resistance in women with polycystic ovary syndrome. Eur. J. Endocrinol. 155 1 (2006) 127-130
23. American Diabetes Association: clinical practice recommendations. Diabetes Care, 23 (Suppl. 1) (2000) S1-116.
24. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 6 (1972) 499-502
25. McAuley K.A., Williams S.M., Mann J.I., Walker R.J., Lewis-Barned N.J., Temple L.A., and Duncan A.W. Diagnosing insulin resistance in the general population. Diab. Care 24 3 (2001) 460-464
26. Sleddens H.F., Oostra B.A., Brinkmann A.O., and Trapman J. Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum. Mol. Genet. 2 4 (1993) 493
27. Bharaj B.S., Vassilikos E.J., and Diamandis E.P. Rapid and accurate determination of (CAG)n repeats in the androgen receptor gene using polymerase chain reaction and automated fragment analysis. Clin. Biochem. 32 5 (1999) 327-332
28. Boorman D.W., Guo Y., Visvanathan K., Helzlsouer K., and O'Brien T.G. Automated fragment analysis method for determining androgen receptor CAG repeat length. Biotechniques 33 1 (2002) 140-143
29. Delmotte F., Simon N., and Leterme J.C. Microsatellite allele sizing: difference between automated capillary electrophoresis and manual technique. Biotechniques 31 4 (2001) 810 814-816, 818
30. Henriquez Sanchez P., Diaz Romero C., Rodriguez Rodriguez E., Lopez Blanco F., Alvarez Leon E., Diaz Cremades J., Pastor Ferrer M.C., and Serra Majem L. Biochemical assessment of nutritional status in the Canary Islands population (1998). Arch. Latinoam Nutr. 50 1 Suppl. 1 (2000) 43-54
31. Serra Majem L., Armas Navarro A., and Ribas Barba L. Food consumption and food sources of energy and nutrients in Canary Islands (1997-98). Arch. Latinoam Nutr. 50 1 Suppl. 1 (2000) 23-33
32. Serra Majem L., Cabrera Leon A., and Sierra Lopez A. Conclusions of the Canary Islands Nutrition Survey (1997-98). Foundations for a nutrition policy in Canary Islands. Arch. Latinoam Nutr. 50 1 Suppl. 1 (2000) 62-70
33. Navarro Rodriguez M.C., Lainez Sevillano P., Ribas Barba L., and Serra Majem L. Anthropometric values and cardiovascular risk factors in Canary Islands (1997-98). Arch. Latinoam Nutr. 50 1 Suppl. 1 (2000) 34-42
34. Brown M.S., and Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 232 4746 (1986) 34-47
35. Croston G.E., Milan L.B., Marschke K.B., Reichman M., and Briggs M.R. Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology 138 9 (1997) 3779-3786
36. Kapoor D., Clarke S., Stanworth R., Channer K.S., and Jones T.H. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 156 5 (2007) 595-602
37. Kapoor D., Malkin C.J., Channer K.S., and Jones T.H. Androgens, insulin resistance and vascular disease in men. Clin. Endocrinol. (Oxf.) 63 3 (2005) 239-250
38. Holmang A., and Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol. Scand. 146 4 (1992) 505-510
39. Livingstone C., and Collison M. Sex steroids and insulin resistance. Clin. Sci. (Lond.) 102 2 (2002) 151-166
40. Shepherd A., and Cleary M.P. Metabolic alterations after dehydroepiandrosterone treatment in Zucker rats. Am. J. Physiol. 246 2 Pt 1 (1984) E123-128
41. Simon D., Preziosi P., Barrett-Connor E., Roger M., Saint-Paul M., Nahoul K., and Papoz L. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 35 2 (1992) 173-177
42. Barrett-Connor E., and Khaw K.T. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78 3 (1988) 539-545
43. Golden S.H., Dobs A.S., Vaidya D., Szklo M., Gapstur S., Kopp P., Liu K., and Ouyang P. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J. Clin. Endocrinol. Metab. 92 4 (2007) 1289-1295
44. Tsai E.C., Matsumoto A.M., Fujimoto W.Y., and Boyko E.J. Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat. Diab. Care 27 4 (2004) 861-868
45. Oh J.Y., Barrett-Connor E., Wedick N.M., and Wingard D.L. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diab. Care 25 1 (2002) 55-60
46. Stellato R.K., Feldman H.A., Hamdy O., Horton E.S., and McKinlay J.B. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diab. Care 23 4 (2000) 490-494
47. Endre T., Mattiasson I., Berglund G., and Hulthen U.L. Low testosterone and insulin resistance in hypertension-prone men. J. Hum. Hypertens. 10 11 (1996) 755-761
48. Amiel S.A., Sherwin R.S., Simonson D.C., Lauritano A.A., and Tamborlane W.V. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N. Engl. J. Med. 315 4 (1986) 215-219
49. Marin P., Holmang S., Jonsson L., Sjostrom L., Kvist H., Holm G., Lindstedt G., and Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int. J. Obes. Relat. Metab. Disord. 16 12 (1992) 991-997
50. Malkin C.J., Pugh P.J., Jones T.H., and Channer K.S. Testosterone for secondary prevention in men with ischaemic heart disease?. QJM 96 7 (2003) 521-529
51. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int. J. Obes. Relat. Metab. Disord. 20 4 (1996) 291-302
52. De Pergola G. The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int. J. Obes. Relat. Metab. Disord. 24 Suppl. 2 (2000) S59-63
53. Leenen R., van der Kooy K., Seidell J.C., Deurenberg P., and Koppeschaar H.P. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J. Clin. Endocrinol. Metab. 78 6 (1994) 1515-1520
54. Couillard C., Gagnon J., Bergeron J., Leon A.S., Rao D.C., Skinner J.S., Wilmore J.H., Despres J.P., and Bouchard C. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J. Clin. Endocrinol. Metab. 85 3 (2000) 1026-1031
55. von Eckardstein A., and Assmann G. High density lipoproteins and reverse cholesterol transport: lessons from mutations. Atherosclerosis 137 Suppl. (1998) S7-11
56. von Eckardstein A., and Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?. Curr. Opin. Lipidol. 11 6 (2000) 627-637
57. Nestler J.E., Jakubowicz D.J., de Vargas A.F., Brik C., Quintero N., and Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab. 83 6 (1998) 2001-2005
58. Dunaif A., and Thomas A. Current concepts in the polycystic ovary syndrome. Annu. Rev. Med. 52 (2001) 401-419
59. Pasquali R., and Filicori M. Insulin sensitizing agents and polycystic ovary syndrome. Eur. J. Endocrinol. 138 3 (1998) 253-254
60. Dahlgren E., Landin K., Krotkiewski M., Holm G., and Janson P.O. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum. Reprod. 13 10 (1998) 2706-2711
61. Diamanti-Kandarakis E., Mitrakou A., Raptis S., Tolis G., and Duleba A.J. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83 8 (1998) 2699-2705
62. Moghetti P., Tosi F., Castello R., Magnani C.M., Negri C., Brun E., Furlani L., Caputo M., and Muggeo M. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J. Clin. Endocrinol. Metab. 81 3 (1996) 952-960